Streetbeat News

Regulatory

SPY

The U.S. Department of the Treasury has announced a new Series I bond rate of 5.27% for the period from November 1 through April 2024. This is an increase from the previous rate of 4.3%.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:13 pm

GTBIF

HITI

SHWZ

TCNNF

VRNOF

Wu-Tang Clan's Raekwon, Charlamagne tha God, and a South Carolina civil rights lawyer have been granted a license to expand the Hashstoria dispensary in Newark, which will feature a cannabis consumption lounge. In Florida, Trulieve Cannabis Corp., Verano Holdings Corp., and Green Thumb Industries Inc. have expanded their retail footprint. Trulieve recently donated an additional $500,000 to Florida's ballot initiative to legalize recreational marijuana. Medicine Man Technologies, operating as Schwazze, announced a cannabis store-within-a-store model in Fort Collins. High Tide Inc. launched sales of recreational cannabis products and consumption accessories at its 157th Canna Cabana branded retail cannabis location in Canada.

Portfolio Pulse from Jelena Martinovic

October 31, 2023 | 2:08 pm

SPY

The USA CB Consumer Confidence for October was reported at 102.6, slightly above the estimated 100, but lower than the previous month's 104.3.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:00 pm

GRTX

Galera Therapeutics Inc (GRTX) stock is sinking after the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese for radiotherapy-induced severe oral mucositis. The company also decided to halt the Phase 2b GRECO-2 trial of rucosopasem manganese in patients with locally advanced pancreatic cancer and the Phase 1/2 GRECO-1 trial of rucosopasem in patients with non-small-cell-lung-cancer, following futility analysis of the GRECO-2 trial. The company's shares are down 51.90% at $0.10.

Portfolio Pulse from Vandana Singh

October 31, 2023 | 1:58 pm

SPY

The Chicago Purchasing Managers' Index (PMI) for October came in at 44, lower than the estimated 45 and the prior figure of 44.1. This indicates a contraction in the manufacturing sector in the Chicago region.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:45 pm

VVPR

VivoPower International PLC (NASDAQ: VVPR) has approved an action plan to address alleged illegal market manipulation, including false information dissemination and naked short selling of its stock. The company has created a Board-led 'Illegal Market Manipulation Task Force' to work with regulators in identifying and prosecuting those involved in market manipulation of VivoPower shares over the past year. VivoPower has engaged an external forensic investigation firm and specialist UK and US legal counsel.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:27 pm

ALNPY

EADSY

RTX

ANA Holdings Inc. plans to inspect Pratt & Whitney's PW1100G-JM engines installed on Airbus SE’s A320neo and A321neo aircraft due to potential issues in the manufacturing of internal engine parts. The inspections will lead to a reduction of approximately 30 flights per day from January to March 2024. RTX Corp, the parent company of Pratt & Whitney, saw its shares close lower by 0.75%.

Portfolio Pulse from Shivani Kumaresan

October 31, 2023 | 1:26 pm

PMCB

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) is preparing for a meeting with the FDA to discuss the further development of its Cell-in-a-Box technology. The company is also evaluating potential opportunities for the use of its $74.6 million cash position. The Cell-in-a-Box technology, along with other potential delivery systems, provides a unique opportunity to treat patients with non-toxic chemotherapeutic prodrugs.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:22 pm

CGEN

Compugen Ltd. (NASDAQ:CGEN) will present new data on its lead pre-clinical asset COM503, a potential first-in-class anti-IL18BP antibody, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2023. The data suggests that COM503 has a leading edge in inhibiting tumor growth while avoiding peripheral toxicity associated with administration of a cytokine. The company plans to file an IND in 2024.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:20 pm

IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data includes a four-year analysis of pooled Cohorts 2 and 4 of the C-144-01 trial, which reports the longest follow-up data on lifileucel treatment outcomes in patients with anti–PD-1–refractory advanced melanoma treated with TIL therapy.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:20 pm